drugset / Trial / NCT02668666
Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer
Phase 2
Completed
49 enrolled
Oana Danciu, MD
Big Ten Cancer Research Consortium · collabPfizer · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a non-randomized, open-label, single-arm, multicenter, phase II study of palbociclib in combination with tamoxifen in women with HR(+)/HER2(-) advanced breast cancer who have not received prior systemic anticancer therapies for their advanced/metastatic disease.
Timeline
- Start
- 2017-02-01
- Primary completion
- 2023-07-03
- Completion
- 2023-10-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Palbociclib | Small molecule | 125 mg | Oral |
| Subject | Tamoxifen | Small molecule | 20 mg | Oral |